M&A Deal Summary

Circassia Pharmaceuticals Acquires Aerocrine

On May 15, 2015, Circassia Pharmaceuticals acquired healthcare services company Aerocrine for 1.8B SEK

Acquisition Highlights
  • This is Circassia Pharmaceuticals’ 1st transaction in the Healthcare Services sector.
  • This is Circassia Pharmaceuticals’ 0th largest (disclosed) transaction.
  • This is Circassia Pharmaceuticals’ 1st transaction in Sweden.

M&A Deal Summary
Date 2015-05-15
Target Aerocrine
Sector Healthcare Services
Buyer(s) Circassia Pharmaceuticals
Deal Type Add-on Acquisition
Deal Value 1.8B SEK

Target

Aerocrine

Solna, Sweden
Aerocrine AB is a medical technology company focused on improving the treatment of patients with inflamed airways. Aerocrine was formed in 1997 and is based in Solna, Sweden.

Search 198,242 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Circassia Pharmaceuticals

Oxford, United Kingdom
Category Company
Founded 2006
Sector Healthcare Services
Employees162
Revenue 24M EUR (2020)
DESCRIPTION

Circassia Pharmaceuticals is a specialty biopharmaceutical company focused on the development of novel immunotherapies. Circassia Pharmaceuticals was founded in 2006 and is based in Oxford, the United Kingdom.

DEAL STATS #
Overall 1 of 2
Sector (Healthcare Services) 1 of 1
Type (Add-on Acquisition) 1 of 2
Country (Sweden) 1 of 1
Year (2015) 1 of 2
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2015-05-18 Prosonix

Oxford, United Kingdom

Prosonix is a UK specialty pharmaceutical company focused on the development of a range of product candidates for the treatment of asthma and COPD. Prosonix's portfolio is based on its proprietary particle engineering technology and Prosonitron reactor system, which enables precise control of pharmaceutical product crystallisation during manufacture, and subsequent delivery characteristics.

Buy £100M
Mergr

Product

Company

Legal